2017 Is Banner Year for Drug Approvals by the Food and Drug Administration

被引：2
|
作者：
Ebied, Alex M. [1 ]
Cooper-DeHoff, Rhonda M. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
来源：
AMERICAN JOURNAL OF MEDICINE | 2018年 / 131卷 / 09期
关键词：
Accelerated approval; Fast track; FDA; New indication; Novel drugs; Priority review;
D O I：
10.1016/j.amjmed.2018.02.034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In 2017. the US Food and Drug Administration approved 46 novel drugs, and 29 drugs received newly approved indications. This record setting year was due in part to the new expedited review pathways. A review of these drugs is summarized. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码：1025 / 1033
页数：9
相关论文
共 50 条
  • [31] Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
    Mitra-Majumdar, Mayookha
    Gunter, Simon J.
    Kesselheim, Aaron S.
    Brown, Beatrice L.
    Joyce, Krysten W.
    Ross, Murray
    Pham, Catherine
    Avorn, Jerry
    Darrow, Jonathan J.
    JAMA NETWORK OPEN, 2022, 5 (05)
  • [32] 2007 FDA drug approvals: a year of flux
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (02) : 107 - 109
  • [33] FEATURES OF NEW DRUG INDICATIONS NOT APPROVED BY THE FOOD AND DRUG ADMINISTRATION, 2008-2017
    Zhang, Audrey D.
    Schwartz, Jason L.
    Ross, Joseph S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S132 - S133
  • [34] 2007 FDA drug approvals: a year of flux
    Bethan Hughes
    Nature Reviews Drug Discovery, 2008, 7 : 107 - 109
  • [35] Comparative benchmarking of regulatory drug approvals by Food & Drug Administration (FDA): A cross disease comparison with gynecologic malignancies.
    Rodriguez-Freixinos, Victor
    Wilson, Michelle K.
    Lheureux, Stephanie
    Martin-Lorente, Cristina
    Karakasis, Katherine
    Wang, Lisa
    Panzarella, Tony
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021
    Glover, Michael
    Hui, Gavin
    Chiang, Ryan
    Savage, Philip
    Krell, Jonathan
    Julve, Maximilian
    Grivas, Petros
    Lythgoe, Mark
    Khaki, Ali Raza
    BJU INTERNATIONAL, 2022, 129 (02) : 168 - 170
  • [37] Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
    Sridhara, Rajeshwari
    Johnson, John R.
    Justice, Robert
    Keegan, Patricia
    Chakravarty, Aloka
    Pazdur, Richard
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (04): : 230 - 243
  • [38] Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
    Enrique Seoane-Vazquez
    Rosa Rodriguez-Monguio
    John H. Powers
    Scientific Reports, 14
  • [39] Use of Clinical Outcome Assessments in New Drug Approvals by the US Food and Drug Administration Divisions of Neurology I and II
    Schein, Yvette
    Fernandez Lynch, Holly
    JAMA NETWORK OPEN, 2022, 5 (09)
  • [40] Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.
    Khaki, Ali Raza
    Desai, Aakash
    Schoen, Martin W.
    Gyawali, Bishal
    Chen, Eddy J.
    Yang, Peter C.
    Warner, Jeremy Lyle
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345